Search: onr:"swepub:oai:gup.ub.gu.se/333146" >
The potential clini...
The potential clinical value of plasma biomarkers in Alzheimer's disease.
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Galasko, Douglas (author)
-
Perneczky, Robert (author)
-
show more...
-
Quevenco, Frances-Catherine (author)
-
van der Flier, Wiesje M (author)
-
Akinwonmi, Akin (author)
-
Carboni, Margherita (author)
-
Jethwa, Alexander (author)
-
Suridjan, Ivonne (author)
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
show less...
-
(creator_code:org_t)
- 2023
- 2023
- English.
-
In: Alzheimer's & dementia : the journal of the Alzheimer's Association. - 1552-5279. ; 19:12, s. 5805-5816
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Many people with cognitive complaints or impairment never receive an accurate diagnosis of the underlying condition, potentially impacting their access to appropriate treatment. To address this unmet need, plasma biomarker tests are being developed for use in Alzheimer's disease (AD). Plasma biomarker tests span various stages of development, including in vitro diagnostic devices (or tests) (IVDs), laboratory-developed tests (LDTs) and research use only devices (or tests) (RUOs). Understanding the differences between each test type is important for appropriate implementation into the AD diagnostic pathway and care continuum.Authors reviewed scientific literature (PubMed, meeting abstracts and presentations, company press releases and websites) on AD plasma biomarkers.This article defines IVDs, LDTs, and RUOs, discusses potential clinical applications and highlights the steps necessary for their clinical implementation.Plasma biomarkers could revolutionize many areas of the AD diagnostic pathway and care continuum, but further research is needed.There is a need for a minimally invasive Alzheimer's disease (AD) diagnostic tool. AD plasma biomarker tests exist at various stages of commercial development. Understanding the development stage of a test is important for its appropriate use. Plasma biomarker tests could function as a triage tool to streamline AD diagnosis. Further steps remain before AD plasma biomarkers can be used routinely.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Humans
- Alzheimer Disease
- Biomarkers
- Cognitive Dysfunction
- diagnosis
- Amyloid beta-Peptides
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Blennow, Kaj, 19 ...
-
Galasko, Douglas
-
Perneczky, Rober ...
-
Quevenco, France ...
-
van der Flier, W ...
-
Akinwonmi, Akin
-
show more...
-
Carboni, Margher ...
-
Jethwa, Alexande ...
-
Suridjan, Ivonne
-
Zetterberg, Henr ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Alzheimer's & de ...
- By the university
-
University of Gothenburg